Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Selling, general and administrative [+] | | | | | | 9.3 | | |
| General and administrative | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.3 | 0.0 | 0.0 |
| Other selling, general and administrative | | | | | | | | |
| Research and development | | | | | | 15.2 | | |
| EBITDA [+] | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | -24.5 | 0.1 | 0.1 |
| EBITDA growth | -5.6% | -9.5% | 4.5% | 14.5% | 21.3% | -22.6% | 19.6% | 24.0% |
| EBITDA margin | | | | | | | | |
| Depreciation and amortization | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| EBIT [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -24.5 | 0.0 | 0.0 |
| EBIT growth | | | | | | -22.6% | | |
| EBIT margin | | | | | | | | |
| Other income (expense), net | -5.3 | -5.1 | -6.9 | -7.0 | -5.4 | 18.3 | -5.3 | -6.3 |
| Pre-tax income | -5.3 | -5.1 | -6.9 | -7.0 | -5.4 | -6.2 | -5.3 | -6.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -5.3 | -5.1 | -6.9 | -7.0 | -5.4 | -6.2 | -5.3 | -6.3 |
| Net margin | | | | | | | | |
| |
| Basic EPS [+] | ($0.13) | ($0.14) | ($0.19) | ($0.19) | ($0.15) | ($0.17) | ($0.15) | ($0.17) |
| Growth | -30.4% | -6.4% | 27.9% | 11.8% | -21.0% | -56.8% | 2.0% | -31.7% |
| Diluted EPS [+] | ($0.13) | ($0.14) | ($0.19) | ($0.19) | ($0.15) | ($0.17) | ($0.15) | ($0.17) |
| Growth | -30.4% | -6.4% | 27.9% | 11.8% | -21.0% | -56.8% | 2.0% | -31.7% |
| |
| Shares outstanding (basic) [+] | 39.7 | 36.7 | 36.5 | 36.5 | 36.4 | 36.2 | 36.3 | 36.3 |
| Growth | 8.8% | 0.8% | 0.5% | 0.5% | 1.8% | 21.2% | 16.5% | 24.1% |
| Shares outstanding (diluted) [+] | 39.7 | 36.7 | 36.5 | 36.5 | 36.4 | 36.2 | 36.3 | 36.3 |
| Growth | 8.8% | 0.8% | 0.5% | 0.5% | 1.8% | 21.2% | 16.5% | 24.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|